Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia

References

• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315. doi: 10.1182/blood-2014-05-578336
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Neas BR, et al. Prevalence of primary immune thrombocytopenia in oklahoma. Am J Hematol. 2012;87(9):848–852. doi: 10.1002/ajh.23262
   PubMed Web of Science ®Google Scholar
• Kuhne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122–2125. doi: 10.1016/S0140-6736(01)07219-1
   PubMed Web of Science ®Google Scholar
• Grace RF, Long M, Kalish LA, et al. Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer. 2012;58(2):216–220. doi: 10.1002/pbc.23112
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):515–519. doi: 10.1097/MOH.0b013e3282ab98c7
   PubMed Web of Science ®Google Scholar
• Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887–895. doi: 10.1182/blood-2002-05-1475
   PubMed Web of Science ®Google Scholar
• Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008;55(2):393–420. doi: 10.1016/j.pcl.2008.01.009
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KM, Nijsten J, Boonacker CW, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295–3307. doi: 10.1182/blood-2014-04-570127
   PubMed Web of Science ®Google Scholar
• Marshall GJ, Powars D, Ewing N, et al. Neutrophilic phagocytosis in autoimmune thrombocytopenia purpura. Am J Pediatr Hematol Oncol. 1982;4(4):375–383. doi: 10.1097/00043426-198224000-00004
   PubMedGoogle Scholar
• Aref S, Selim T, Ibrahim L, et al. Flowcytometry detection of platelets autoantibodies in children with idiopathic thrombocytopenic purpura. Indian J Hematol Blood Transfus. 2009;25(3):96–103. doi: 10.1007/s12288-009-0028-0
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369(6481):568–571. doi: 10.1038/369568a0
   PubMed Web of Science ®Google Scholar
• Sasazawa Y, Sato N, Suzuki T, et al. C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling. Biochem. Biophys. Res. Commun. 2015;468(1–2):262–268. doi: 10.1016/j.bbrc.2015.10.116
   PubMed Web of Science ®Google Scholar
• Ghanima W, Holme PA, Tjønnfjord GE. Immune thrombocytopenia- pathophysiology and treatment. Tidsskr Nor Laegeforen. 2010;130(21):2120–2123. doi: 10.4045/tidsskr.09.1119
   PubMedGoogle Scholar
• Kuter DJ. Milestones in understanding platelet production: a historical overview. Br. J. Haematol. 2014;165(2):248–258. doi: 10.1111/bjh.12781
   PubMed Web of Science ®Google Scholar
• Qian S, Fu F, Li W, et al. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood. 1998;92(6):2189–2191.
   PubMed Web of Science ®Google Scholar
• Sungaran R, Chisholm OT, Markovic B, et al. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood. 2000;95(10):3094–3101.
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369(6481):565–568. doi: 10.1038/369565a0
   PubMed Web of Science ®Google Scholar
• Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85(2):391–401.
   PubMed Web of Science ®Google Scholar
• Forsberg EC, Prohaska SS, Katzman S, et al. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet. 2005;1(3):e28. doi: 10.1371/journal.pgen.0010028
   PubMed Web of Science ®Google Scholar
• Methia N, Louache F, Vainchenker W, et al. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood. 1993;82(5):1395–1401.
   PubMed Web of Science ®Google Scholar
• Hattori H, Kuwayama M, Takamori H, et al. Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP. Rinsho Ketsueki. 2014;55(12):2429–2432.
   PubMedGoogle Scholar
• Hitchcock IS, Chen MM, King JR, et al. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood. 2008;112(6):2222–2231. doi: 10.1182/blood-2008-01-134049
   PubMed Web of Science ®Google Scholar
• Gu J, Lu L, Xu R, et al. Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl). 2002;115(7):983–986.
   PubMed Web of Science ®Google Scholar
• Makar RS, Zhukov OS, Sahud MA, et al. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12):1041–1044. doi: 10.1002/ajh.23562
   PubMed Web of Science ®Google Scholar
• Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259–270. doi: 10.1007/s12185-015-1837-6
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Macahilig C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3):255–263. doi: 10.1007/s12185-014-1731-7
   PubMed Web of Science ®Google Scholar
• Vilaplana V E, Aragones JH, Fernandez-Llamazares CM, et al. Use of romiplostim for primary immune thrombocytopenia in children. Pediatr Hematol Oncol. 2012;29(2):197–205. doi: 10.3109/08880018.2011.629401
   PubMed Web of Science ®Google Scholar
• Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol. 2014;164(2):266–271. doi: 10.1111/bjh.12609
   PubMed Web of Science ®Google Scholar
• Seidel MG, Urban C, Sipurzynski J, et al. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia. Br J Haematol. 2014;165(3):419–421. doi: 10.1111/bjh.12766
   PubMed Web of Science ®Google Scholar
• Ramaswamy K, Hsieh L, Leven E, et al. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr. 2014;165(3):600–605.e4. doi: 10.1016/j.jpeds.2014.03.060
   PubMed Web of Science ®Google Scholar
• Eser A, Toptas T, Kara O, et al. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study. Blood Coagul Fibrinolysis. 2016;27(1):47–52. doi: 10.1097/MBC.0000000000000380
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi: 10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang Y, Shi H. Expression of thrombopoietin related genes in patients with idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi. 1998;19(11):587–589.
   PubMedGoogle Scholar